The current course of acute respiratory infections and the possibility of pathogenetic therapy.
Acute respiratory viral infections (ARVI) are leading in the structure of the general morbidity of the population. To date, more than 200 viruses that affect the respiratory tract and ENT organs are known [1]. The reservoir of ARVI pathogens is only human, the highest incidence is observed in the cold season [8]. It is also possible to infect several ARVI pathogens together, which is accompanied by a severe course of the disease and the addition of bacterial complications [6, 7]. To date, prevention and treatment of ARVI, both in adults and children, is one of the important tasks facing the medical community [1, 2]. The etiotropic therapy of most ARVI has not been developed, and the use of interferon preparations and interferon synthesis inducers has not proved their clinical efficacy [11]. As an alternative, bioregulatory agents that have proven their safety and clinical efficacy can be used [12]. The article presents numerous studies of clinical efficacy and safety of the bioregulatory drug Engystol in different age groups.